US OptionsDetailed Quotes

ENOV250117C50000

Watchlist

0.60
0.000.00%

15min DelayClose Dec 23 16:00 ET

0.00High0.00Low

Enovis Corp Stock Discussion

Moomoo AI

Feb 26 07:55

The company's use of debt is seen as risky due to its EBIT loss and the liabilities it has. The balance sheet is not considered strong, but it could improve over time. The stock is considered quite risky.

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Moomoo AI

Feb 25 17:55

Needham analysts predict Enovis's new products, orthopedic market strength, and the Lima acquisition will exceed 2024 consensus. They also foresee Paragon 28 returning to roughly 20% revenue growth in 2024 due to new bunion-focused products, supply chain enhancements, and sales force growth.

Needham Sees Orthopedics Market Slowing; Favors Enovis, Paragon 28

Moomoo AI

Dec 5, 2023 05:10

Enovis CEO Matt Trerotola praised Shirley, Vogt, and Ross for their roles in the company's growth. He highlighted Shirley's influence on Enovis's transformation to a medtech firm, Vogt's contribution to the U.S. surgical business growth, and Ross's work in ensuring sustained growth in the P&R segment.

Press Release: Enovis Announces Business Segment Leadership Transition Plan

Moomoo AI

Nov 30, 2023 07:01

Enovis' falling revenue and absent profits might have led to a drop in share price. Viewing the total shareholder return and recent share price rise, the company may suggest investment potential if it shows sustainable long term growth.

Enovis (NYSE:ENOV) Shareholders Have Endured a 21% Loss From Investing in the Stock Three Years Ago

Moomoo AI

Nov 3, 2023 09:26

Enovis's rise in liabilities and recent EBIT loss spark concerns about its debt use and future profitability. With a negative free cash flow of US$106m over the past year, the company's financial risk is evident. Balance sheet situation calls for caution due to dubious circumstances.

Would Enovis (NYSE:ENOV) Be Better Off With Less Debt?

Analysts Notebook

Jun 26, 2023 07:11

Columns US Top Rating Updates on 6/26: MRNA, GOOG, TSLA, TXRH and More

$Cheesecake Factory (CAKE.US)$ initiated at equal-weight by Wells Fargo, announced target price at $33.00.
$Texas Roadhouse (TXRH.US)$ initiated at equal-weight by Wells Fargo, announced targe price at $113.00.
$Moderna (MRNA.US)$ was upgraded by UBS from neutral to buy, but decreased target price from $221.00 to $191.00.
$Sotera Health Company (SHC.US)$ was upgraded by Keybanc from neutral to buy, announced target price at $24.00.
$Alphabet-C (GOOG.US)$ was downg...

Analysts Notebook

May 12, 2023 08:30

Columns US Top Rating Updates on 5/12: EA, DIS, TWLO, FOXA and More

$Disney (DIS.US)$Cut to Peer Perform From Outperform by Wolfe Research.
Disney Cut to Peer Perform From Outperform by Wolfe Research.
$Twilio (TWLO.US)$Cut to Neutral From Buy by Mizuho
Twilio shares slipped around 1% in pre-market trading on Friday after investment firm Mizuho downgraded the communications software company, citing "near-term" challenges.
$Electronic Arts Inc (EA.US)$Raised to Buy From Hold by DZ Bank
DZ Bank analyst Markus...

Analysts Notebook

Jun 16, 2022 06:30

Columns Top upgrades and downgrades on 6/16: BA, DG, U, WSO and more

Upgrades
• $ACADIA Pharmaceuticals (ACAD.US)$ : Jefferies Upgrades to Buy from Hold - PT $25 (from $22)
• $Arthur J. Gallagher (AJG.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $185 (from $182)
• $Apple Hospitality REIT Inc (APLE.US)$ : B.Riley Upgrades to Buy from Neutral - PT $19
• $AutoZone (AZO.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $2,420 (from $2,125)
• $Boeing (BA.US)$ : Citigroup Upgr...

No comment yet